Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis

Медицинский совет

N. Y. Lasch¹ 

[1] Neurosurgery and Medical Genetics of the Russian National Research Medical University named after N.I. Pirogov;

关键词: рассеянный склероз;    препараты;    изменяющие течение рассеянного склероза;    терифлуномид;    multiple sclerosis;    teriflunomide;    multiple sclerosis sease-modifying medications;   

DOI  :  10.21518/2079-701X-2015-18-63-67

来源: DOAJ

【 摘 要 】

New immunomodulatory drugs for the treatment of multiple sclerosis are emerging today in the pharmaceutical market. In Russia, new first line preparation - teriflunomide 14 mg in tablet form - was recently granted approval for the treatment of patients with remitting MS. The drug demonstrated good tolerability, efficacy and relative safety in long-term clinical trials. The article discusses an algorithm for the management of patients with RMS aimed at reducing the risk of adverse events associated with teriflunomide therapy.

【 授权许可】

Unknown